REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
Healthcare
$7.26 +1.97%
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
52W Low $5.46High $16.19
Volume 0.70M
Average 1.24M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$123.96M
FY 2025 · Annual
Investing Cash Flow
-$15.87M
FY 2025 · Annual
Financing Cash Flow
$116.77M
FY 2025 · Annual
+26.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| Deferred Income Tax | (1.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 38.81M | 40.79M | 40.27M | 38.46M | 34.56M |
| Change in Working Capital | 40.22M | 13.98M | (10.89M) | 5.53M | 11.78M |
| Accounts Receivables | 14.12M | 4.82M | 3.94M | 9.71M | (7.66M) |
| Inventory | 29.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.3M) | 18.79M | (2.79M) | (292K) | (2.28M) |
| Other Working Capital | (899K) | (9.64M) | (12.03M) | (3.88M) | 21.73M |
| Other Non-Cash Items | 4.36M | 5.16M | (1.61M) | (6.23M) | 7.96M |
| Operating Cash Flow | 218.88M | (207.49M) | (218.41M) | (173.13M) | (123.96M) |
| Capital Expenditures | (84.18M) | (30.72M) | (9.96M) | (2.44M) | (2.41M) |
| Acquisitions (Net) | (4.99M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (498.14M) | (184.88M) | (86.56M) | (190.14M) | (332.63M) |
| Sales of Investments | 175.68M | 203.67M | 287.47M | 290.24M | 319.11M |
| Other Investing Activities | 4.99M | 0 | 0 | 5.78M | 62K |
| Investing Cash Flow | (406.64M) | (11.93M) | 190.94M | 103.45M | (15.87M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 218.21M | 1.74M | 6.7M | 131.07M | 1.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 1.19M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.96M) | (30.58M) | (41.67M) | (39.58M) | 115.76M |
| Financing Cash Flow | 195.25M | (28.84M) | (34.97M) | 92.68M | 116.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.48M | (248.26M) | (62.43M) | 23M | (23.06M) |
| Free Cash Flow | 134.7M | (238.21M) | (228.37M) | (175.56M) | (126.38M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$193.9M
+ D&A$15.6M
+ Stock-Based Comp$34.6M
+ Deferred Tax$0
+ Working Capital$11.8M
+ Other Non-Cash$8.0M
= Operating Cash Flow-$124.0M
- Capex-$2.4M
= Free Cash Flow-$126.4M
Analysis
FY2025 free cash flow is -$126.4M. FCF conversion is 65.2% of net income. Operating cash flow was -$124.0M, with capex of -$2.4M. The largest bridge item is Stock-Based Comp at $34.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
Does RGNX generate free cash flow?
REGENXBIO Inc. (RGNX) generated -$126.38M of free cash flow in fiscal 2025.
How much operating cash flow does RGNX produce?
Operating cash flow was -$123.96M, before capital expenditures of $2.41M.
Continue the stock analysis
Jump to another research area for this company.